ALX raises $105M for midphase trials of CD47 cancer drug

cafead

Administrator
Staff member
  • cafead   Feb 12, 2020 at 10:32: AM
via ALX Oncology has raised $105 million. The series C round will support phase 2 trials of CD47 myeloid checkpoint inhibitor ALX148 in combination with other anti-cancer therapies.

article source
 

<